EUCTR2011-002768-25-DK进行中（未招募）不适用
A Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Osteoarthritis Knee Pain - Study of BOTOX® in the treatment of Osteoarthritis Knee Pain
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, 40 to 75 years of age on the day of randomization (day 1).
- •2. Written informed consent and data protection consent has been obtained prior to initiating any study specific procedures.
- •3. Primary idiopathic knee OA diagnosed in accordance with the ACR modified clinical classification criteria (Altman et al, 1986; Altman 1991) and verified radiologically as Kellgren-Lawrence grade I, II or III (Kellgren and Lawrence, 1957).
- •4. For the study knee, the average daily worst pain score over the 14 days prior to day 1 (ie, days -14 to day -1) must be 4.0 to 9.0. The 14-day average score will be derived from daily worst pain scores recorded in a diary for the study knee.
- •5. Stable knee pain in the study knee for = 6 consecutive months prior to visit 1. No evidence of abnormal mechanical symptoms such as locking or catching of the study knee per medical history or physical examination.
- •6. Body weight = 40 kg and = 150 kg with a body mass index (BMI) of 19 to = 40 kg/m2 inclusive.
- •7. For females of childbearing potential, a negative urine pregnancy test at screening, baseline, and on the day of the treatment (prior to the administration of the study medication) is required.
- •8. Must be ambulatory without assistive walking devices, able to perform usual daily activities, and agree to maintain the similar activity level throughout the course of the study.
- •9. Ability to follow study instructions and likely to complete all required visits.
- •10. Stable medical condition, in the investigator’s opinion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Patient diagnosed with any condition suggestive of a secondary cause of knee OA including but not limited to knee trauma, articular fracture, major dysplasias or congenital abnormality, acromegaly, ochronosis, hemochromatosis, Wilson’s disease,or primary osteochondromatosis.
- •2. History of or current evidence of rheumatoid arthritis as diagnosed by ACR criteria, or history of prior synovial fluid analysis of the study knee showing a white blood cell count =2000 mm3 that is indicative of a diagnosis other than OA.
- •3. Presence of bursitis or tear of meniscus or ligament of the study knee, or history of significant knee injury to the study knee within 1 year of visit 1.
- •4. History of surgery in the study knee within 24 weeks prior to visit 1, or already planned surgery of the study knee such as, arthroplasty, arthroscopy inspection, or repair of knee ligaments.
- •5. Treatment with IA hyaluronic acid in the study knee within 24 weeks prior to visit 1.
- •6. Treatment with IA corticosteroid in any joint or intramuscular corticosteroid administration within 12 weeks prior to visit 1.
- •7. Concurrent chronic pain conditions such as back pain, hip pain (eg, disc herniation, peripheral nerve entrapment, multiple sclerosis), fibromyalgia that may interfere with assessment of the study knee. The study knee pain should be the predominant pain.
- •8. History or current diagnosis of gout or pseudogout with knee involvement.
- •9. History or current diagnosis of Reiter’s, Sjögren’s syndrome, psoriasis or systemic lupus erythematosus or other autoimmune diseases with joint involvement.
- •10. Patients at a high risk of joint infection complication (eg, infection of local skin, soft tissue and joint in the study knee, indwelling urinary catheter) or have immunocompromised conditions (eg, known HIV or organ transplant).
- •11. Evidence of abnormal coagulation status (eg, excessive tooth bleeding with brushing, abnormal bleeding time, partial thromboplastin time or prothrombin time) or patients with hemophilia or other blood diseases affecting coagulation (eg, aplastic anemia, leukemia, or under chemo-/radio-therapy).
- •12. Patients continue to take excluded analgesic medications after visit 2.
- •13. Patients with contraindications to the use of paracetamol (ie, rescue medication for this study).
- •14. History of severe, progressive, or current unstable medical conditions other than OA such as renal, hepatic, gastrointestinal, neurological, endocrine, metabolic, degenerative bone disorders, respiratory, and/or psychiatric disorder as determined by medical history, physical examination and /or laboratory tests.
- •15. History of severe cardiovascular diseases, stroke, recurrent seizures, frequent or severe allergic reactions to multiple medications.
- •16. Electrocardiogram (ECG) abnormality at screening that in the opinion of the investigator could increase risk associated with participation in the study.
- •17. Patients with an active malignancy of any type or a history of malignancy within the last 5 years (except basal cell carcinoma of the skin that has been excised at least 12 weeks prior to study start).
- •18. Have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.
- •19. Patient Health Questionnaire-9 (PHQ-9) score of >15 or a score of > 0 on item #9 of the PHQ-9 at week -4.
- •20. Known allergy or sensitivity to the study medication(s) or its components.
- •21. Females who are pregnant, nursing, or planning a pregnancy dur
研究者
相似试验
进行中（未招募）
1 期
Part 1 and Part 3: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of AC-101Oral and Gastrointestinal - Inflammatory bowel diseaseInflammatory Bowel DiseaseACTRN12623000234617Accro Bioscience (Australia) Pty Ltd70
进行中（未招募）
1 期
A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) with or without T-ChOSTM as adjuvant therapy in patients with surgically resected pancreatic cancerEUCTR2014-001163-12-DKHerlev University Hospital, Oncology Dept.180
招募中
不适用
Intervention Study to evaluate Body Fat Reduction Efficacy and Safety of 'BN-202M' in Overweight SubjectsKCT0007268Hecto Healthcare100
进行中（未招募）
Unknown
A clinical trial to study the safety and immunogenecity (the ability of a molecule or substance to provoke an immune response”) of Varicella zoster virus vaccine in healthy male and female adultsVaricella-zoster VirusInfection - Studies of infection and infectious agentsACTRN12623000947606Bestudy Australia Pty Ltd100
暂停
不适用
A single center, randomized, double-blind, placebo-controlled, single and multiple-dose study of DEB025 (alisporivir) in healthy Chinese and Caucasian subjectsFactors influencing health status and contact with health serviscesKCT0000363Seoul National University Hospital36